Tecan Group AG · SIX:TECN
Tecan — Investor Day (June 2016)
125 slides from Tecan's investor day presentation, Jun 16, 2016
Slide 1: Capital Markets Day
Tecan Group Capital Markets Day MAENNEDORF, 16 JUNE 2016
Slide 2: Agenda
Agenda Advancing Tecan David Martyr Life Sciences Business 08:45 – 10:00 Strategy and Growth Drivers Stefan Traeger Customer Needs Driving Solutions James O’Brien Expanding Our Reagents Business Geert Nygaard 10:00 – 10:15 Coffee Break Partnering Business Strategy and Growth Drivers Achim von Leopre
Slide 3: Advancing Tecan
Tecan Group Capital Markets Day ADVANCING TECAN DR. DAVID MARTYR, CEO
Slide 4: Advancing Tecan
Advancing Tecan • Accelerating topline growth • 2015: +13.1%, highest rate since 2006 SALES • Outgrowing the market • Organic: +9.6%, clearly above market • Expand operating margins • 2015: EBITDA margin up by 200 bps PROFITABILITY • Focus on operational efficiency • Net profit even stronger • M&A t
Slide 5: Video
(CLICK THE VIDEO TAB ON THE WEBCAST TO WATCH VIDEO)
Slide 6: Tecan's Vision Statement
Tecan’s Vision Statement Our vision is to empower every laboratory, every day, around the world with Tecan technology, products and support. We will help to shape the future of automated workflows in life sciences and clinical diagnostics through unrivaled expertise, products and customer support. 6
Slide 7: Tecan in the Center of a Dynamic Environment
Tecan in the Center of a Dynamic Environment Genomics LCMS Molecular Biobanking Diagnostics Synthetic Immuno Biology Diagnostics Cell Biology Protein Next-Gen Histology Sciences Sequencing Pathology Applied Markets CRISPR …and Liquid many more Biopsies 7
Slide 8: Tecan's Products, Business Structure and Markets
Tecan’s Products, Business Structure and Markets LIFE SCIENCES BUSINESS PARTNERING BUSINESS • Focused on all end-user activities • Focused on all OEM activities • Products marketed under the Tecan brand • Products sold by partners under their own through own sales & service organizations and brand d
Slide 9: Transition from Research to Diagnostics
Transition from Research to Diagnostics TECAN HAS A UNIQUE POSITION TO BRIDGE FROM RESEARCH TO DIAGNOSTICS SETTINGS LIFE SCIENCE RESEARCH LAB DEVELOPED TESTS (LDT) IN-VITRO DIAGNOSTICS Life Sciences Life Sciences Partnering Business Business Business EXAMPLES • Next-Generation Sequencing (NGS) • Mas
Slide 10: Life Sciences Business and Partnering Business
Life Sciences Business and Partnering Business Maximizing Value Generation LIFE SCIENCES BUSINESS PARTNERING BUSINESS • Early exposure to new • Fully IVD compliant technologies and applications solutions for global rollout in Research (RUO) setting • Custom-built or platform • Deep expertise in emer
Slide 11: Basis for Corporate Strategy: Market Structure
Basis for Corporate Strategy: Market Structure LIFE SCIENCE RESEARCH IN-VITRO DIAGNOSTICS STRATEGIC PILLARS CAGR +3-5% +3-5% 1 Scale & > 40 BN USD > 40 BN USD capability Reagents & Consumables 3 Reagents & Consumables 2 Build additional pillars and complete portfolio 2 Instruments 3 Offer Instrument
Slide 12: Priorities for 2016
Priorities for 2016 • Material cost savings • Supply chain management Operational efficiency • Productivity projects • Maintaining fast pace of innovation • New product launches • Delivery ramp-up Partnering Business • Concluding new development agreements • Sias integration • Growth from new instru
Slide 13: Life Sciences Business – Strategy and Growth Drivers
Capital Markets Day LIFE SCIENCES BUSINESS – STRATEGY AND GROWTH DRIVERS STEFAN TRAEGER, EXECUTIVE VP LIFE SCIENCES BUSINESS
Slide 14: Tecan LSB with positive momentum
Tecan LSB with positive momentum SALES – LIFE TECAN LSB WITH +11.8% AND +6.7% ORGANIC IN 2015 (LC) SCIENCES BUSINESS (CHF million) EBIT MARGIN EXPANDED BY +70 BPS IN THE SAME PERIOD 253.0 236.3 INTERNAL DRIVERS 223.7 Changes in organizational structure • Transitioned from product-line structure to c
Slide 15: LSB Initiatives embedded in Corporate Strategic Frame
LSB Initiatives embedded in Corporate Strategic Frame LIFE SCIENCE RESEARCH IN-VITRO DIAGNOSTICS STRATEGIC PILLARS CAGR +3-5% +3-5% 1 Expanding the Core > 40 BN USD > 40 BN USD Business 2 Building up future pillars in the instrument Reagents & Consumables 3 Reagents & Consumables market 3 Expansion
Slide 16: Applicative trends driving customer demands
Applicative trends driving customer demands 1 Expanding the Core Business Trends in Cell Biology reveal a shift towards analyzing life Trends in Genomics show NGS expanding its footprint Trends in Discovery show continued outsourcing and more diversity in the approach WITH NEW PRODUCT PLATFORMS, WE
Slide 17: Major Platform Launches: FLUENT
Major Platform Launches 1 Expanding the Core Business FLUENT™* NEXT GENERATION LIQUID HANDLING Setting new standards for simplicity, PLATFORM FAMILY productivity and confidence UPDATE PRODUCT ANNOUNCEMENTS: • Jun 2014: Cell Biology • Feb 2015: Compound Management • Feb 2015: New modules for increase
Slide 18: Major Platform Launches: SPARK
Major Platform Launches 1 Expanding the Core Business SPARK ®* NEXT GENERATION ALL-NEW MULTIMODE READER PLATFORM MICROPLATE READER PLATFORM Greater flexibility, increased speed and productivity UPDATE SPARK 10M LAUNCHED AT SLAS2015: • Designed for cell biology and genomics customers • Launch of addi
Slide 19: Acquisition of IBL International
Acquisition of IBL International has enabled Tecan to offer solutions specialty diagnostics 3 Expansion of recurring revenues REAGENTS & AUTOMATION – PERFECT MATCH August 2014: Acquisition of IBL International • Established and leading immunoassay (IA) company for specialty diagnostics • Supports ev
Slide 20: LSB with 45% of sales in recurring revenues
Life Sciences Business with 45% of sales in recurring revenues – potential for further profitable growth in consumables 3 Expansion of recurring revenues GROWTH OPPORTUNITIES IN PLASTICS CONSUMABLES Sales by Products (in % of LSB sales) 1 Drive share of wallet / commercial push to capture installed
Slide 21: Expanding the addressable market
Expanding the addressable market 2 Building up future pillars in the instrument market LIFE SCIENCE RESEARCH IN-VITRO DIAGNOSTICS STRATEGIC DIRECTION CAGR +3-5% +3-5% • Build up further pillars in > 40 BN USD > 40 BN USD the life science tools market Reagents & Consumables Reagents & Consumables • I
Slide 22: Summary
Summary LIFE SCIENCES BUSINESS WITH POSITIVE MOMENTUM IN THE LAST 2 YEARS • Major new products launched • Organizational changes implemented and processes improved • Expanded into the reagent business STRATEGIC TRAJECTORIES LEADING INTO THE NEXT PHASE • Based on improved product portfolio and busine
Slide 23: Needs Drive Our Solutions
Capital Markets Day LIFE SCIENCES BUSINESS – NEEDS DRIVE OUR SOLUTIONS JAMES OBRIEN, HEAD OF LIFE SCIENCE AND APPLIED MARKETS
Slide 24: Trends in Cell Biology
Trends in Cell Biology reveal a shift towards analyzing life Move to ‘closer to human’ cellular models Attention continues on Biologics away from Small Molecule Personalized medicines and stem cell discovery become closer to treatment High-content data acquisition & analysis moves from HCS environme
Slide 25: Trends in Genomics
Trends in Genomics show NGS expands footprint while classical genomics drive market CRISPR/Cas9 is gaining attention and customers begin looking for automation for scale NGS is replacing arrays in many markets Classical genomics workflows need to scale with NGS demand Cost pressures on reaction cost
Slide 26: Trends in Discovery
Trends in Discovery shows continued outsourcing to CROs and more diversity in discovery approach Modular approaches to workflows are considered vs full integration CROs offering assay development services to CROs Outsourcing of high throughput screening to CROs and smaller scale screening to academi
Slide 27: Trends become the needs of the customer
Trends become the needs of the customer Market Trends CRISPR/Cas9 is gaining Modular approaches to Move to ‘closer to human’ attention and customers workflows are considered cellular models begin looking for vs full integration automation for scale Attention continues on CROs offering assay NGS is r
Slide 28: New applications to be realized with fewer experts
New applications to be realized with fewer experts CRISPR/Cas9 is gaining Modular approaches to Move to ‘closer to human’ attention and customers Market Trends cellular models begin looking for workflows are considered vs full integration automation for scale Many new applications to be mastered to
Slide 29: Ease of Use
Ease of Use FLUENT ® SPARK ® D300e LABORATORY AUTOMATION SOLUTION MULTIMODE READER PICO-LITER DISPENSER • Intuition built-in via standard • SparkControl software built • Clear, Intuitive software operator-centric touch around one click applications guides user through every interface for routine ass
Slide 30: Customers look to vendors for solutions
Customers look to vendors for solutions Attention continues on CROs offering assay NGS is replacing arrays Market Trends Biologics away from in many markets development services Small Molecule to CROs With many new applications entering their workflows, Customers need a solution that does not requir
Slide 31: Application Specific Solutions
Application Specific Solutions FLUENT ® SPARK ® D300e LABORATORY AUTOMATION SOLUTION MULTIMODE READER PICO-LITER DISPENSER • Application specific • One touch applications • Native wizards to simplify configurations for cell-based simplify the user interaction creation of complex plate assays and com
Slide 32: Throughput needs to address the customer problem
Throughput needs to address the customer problem Personalized medicines Outsourcing of high Classical genomics and stem cell discovery throughput screening to Market Trends become closer to workflows need to scale CROs and smaller scale with NGS demand treatment screening to academia Products must m
Slide 33: Optimal Scale
Optimal Scale FLUENT ® SPARK ® D300e LABORATORY AUTOMATION SOLUTION MULTIMODE READER PICO-LITER DISPENSER • Dynamic deck is freely (re-) • Spark 10M and 20M cover • Broad range: Dispense from configurable in all dimensions spectrum of requirements picoliters to microliters • Future proofing with arm
Slide 34: Return on investment is evaluated across workflow
Return on investment is evaluated across workflow High-content data Cost pressures on Future proofing of acquisition & analysis reaction costs as more products becomes Market Trends moves from HCS spend for NGS stronger focus as future environment processing is more dynamic Total return on investmen
Slide 35: Return on Investment
Return on Investment FLUENT ® SPARK ® D300e LABORATORY AUTOMATION SOLUTION MULTIMODE READER PICO-LITER DISPENSER • High precision pipetting and • Automated confluence • Reduced consumption of detection sensitivity reduce measurement to save time of compounds by eliminating sample and reagent volumes
Slide 36: The needs of customers drive our products
The needs of customers drive our products Market Trends Customer Needs CRISPR/Cas9 is gaining Modular approaches to Ease of Move to ‘closer to human’ attention and customers workflows are considered cellular models begin looking for vs full integration Use automation for scale Attention continues on
Slide 37: Update Reagents Business
Capital Markets Day Update Reagents Business GEERT NYGAARD, MANAGING DIRECTOR IBL INTERNATIONAL
Slide 38: Immunoassay Reagent Business
Immunoassay Reagent Business • Production of IBL International in Hamburg, Germany ~ 90 employees • Full product pipeline of specialty ELISA based Immunoassays • Covers the complete value chain from product development and production up to worldwide sales • TÜV and FDA audited manufacturing faciliti
Slide 39: Strong Specialized Product Portfolio
Strong Specialized Product Portfolio Focus Neuroscience: Autoimmunity Neurodegeneration, Neurotransmitters ARAb, MUSK, Spermatozoa Ab, dsDNA Amyloid-β, Tau, Catecholamines Endocrinology Infectious Diseases 17-OH Progesterone, Free-Testosteron, Borrelia, H. pylori, Hantavirus, HIB, Vitamin-D, Active
Slide 40: Example: HMGB1
Example: HMGB1 • HMGB1 – key mediator of the immune system • Broad use in all relevant pathological conditions, especially cancer, diabetes, autoimmune diseases and general immunology • Recognized as “gold standard” by relevant Key-Opinion-Leaders • Allows for sample testing in all types of body flu
Slide 41: Example: Saliva Diagnostics
Example: Saliva Diagnostics • Niche but fast growing market • Saliva is increasingly used as the specimen of choice in a variety of medical care situations and emerging areas of health measurement and monitoring • Saliva sampling is non-invasive, painless and very convenient, with no need for medica
Slide 42: Progress - Immunoassay Reagent Business
Progress - Immunoassay Reagent Business SALES BY PRODUCT GROUP Reagent Business grew high single digits in GROUP 2015, above market rate SALES Reagents 5% of total group sales and 8% of Instruments 5% division sales in 2015 11% Services Consumables 22% 62% • Integration into Tecan finalized Reagents
Slide 43: Expansion of recurring reagent revenues
3 Expansion of recurring reagent revenues LIFE SCIENCE RESEARCH IN-VITRO DIAGNOSTICS STRATEGIC DIRECTION CAGR +3-5% +3-5% > 40 BN USD > 40 BN USD Expanding IA product range • new in-house developed • in licensed products Reagents & Consumables 3 Reagents & Consumables Offering automated IA solutions
Slide 44: Progress - Immunoassay Reagent Business
Progress - Immunoassay Reagent Business Immunoassay Reagents fully integrated into the Tecan product offering Marketing channels aligned leveraging the Tecan market position • Strategic plan in place • R&D roadmap defined • Internet presence fully integrated including US webshop • Marketing material
Slide 45: Generate incremental reagent revenue stream
Generate incremental reagent revenue stream • Drive new instrument placements by offering integrated solutions • Leverage the global Tecan organization to increase geographic reach • Sell reagents to existing Tecan customer base 22 INCREMENTAL % RECURRING REVENUE STREAM 45
Slide 46: Solutions Provider for Specialty Diagnostics
Solutions Provider for Specialty Diagnostics • IBL International immunoassays adapted to the Freedom EVOlyzer platforms • 30+assays already adapted, further assays in process 46
Slide 47: Leveraging the Global Tecan Organization
Leveraging the Global Tecan Organization • Tecan US direct distribution of IA products gone live in January 2016 • Italy gone live in May 2016 • China and Benelux expected to go live within the next months • Further countries for direct distribution in planning 47
Slide 48: Agenda
Agenda Advancing Tecan David Martyr Life Sciences Business 08:45 – 10:00 Strategy and Growth Drivers Stefan Traeger Customer Needs Driving Solutions James O’Brien Expanding Our Reagents Business Geert Nygaard 10:00 – 10:15 Coffee Break Partnering Business Strategy and Growth Drivers Achim von Leopre
Slide 49: Partnering Business – Strategy and Growth Drivers
Capital Markets Day PARTNERING BUSINESS – STRATEGY AND GROWTH DRIVERS ACHIM VON LEOPRECHTING, EXECUTIVE VP PARTNERING BUSINESS
Slide 50: Continuing growth in the Partnering Business
Continuing growth in the Partnering Business SALES – PARTNERING BUSINESS GREW +14.9% IN 2015 (LOCAL) PARTNERING BUSINESS (CHF million) EBIT MARGIN INCREASED TO 16% OF SALES 187.3 GROWTH DRIVERS 164.6 163.2 Continuing ramp up of platforms • US launch of FDA cleared ORTHO Vision™ Analyzer by Ortho Cli
Slide 51: Reasons To Consider OEM Partnering Approach
Reasons To Consider OEM Partnering Approach TIME TO MARKET / TIME TO REVENUE • Proven off-the-shelf solutions available • Development and Support teams with experience in specific technologies R&D CAPACITY • Extend internal capacity • Augment internal technical expertise TECHNOLOGY ACCESS • Modules,
Slide 52: Trends in the IVD Industry
Trends in the IVD Industry • The IVD sector is currently very dynamic, with many new technologies transitioning into this sector • Historically, even many of the top 15 IVD companies have been focused on defined segments or applications • New technologies open up new market opportunities • Companies
Slide 53: Focus on Growth Segment Applications
Focus on Growth Segment Applications MOLECULAR DIAGNOSTICS • Genomics • Personalized healthcare HIGH GROWTH • Companion Diagnostics HISTOLOGY/ PATHOLOGY HIGH GROWTH • Non-Invasive Prenatal Testing (NIPT) • Oncology Liquid Biopsies (cfDNA, CTCs) ELISA IMMUNOASSAY HIGH GROWTH ASIA MED GROWTH ROW • Pat
Slide 54: Oncological Diagnostics – Multi-Technology Deployment
Oncological Diagnostics – Multi-Technology Deployment Creating “Tumor Fingerprints” for Personalized Medicine • Prediction • Early detection • Monitoring TISSUE IHC FISH NGS PCR MS Components, Modules, Systems, Consumables, Support, Service 54
Slide 55: Transition from Research to Diagnostics
Transition from Research to Diagnostics TECAN HAS A UNIQUE POSITION TO BRIDGE FROM RESEARCH TO DIAGNOSTICS SETTINGS LIFE SCIENCE RESEARCH LAB DEVELOPED TESTS (LDT) IN-VITRO DIAGNOSTICS Life Sciences Life Sciences Partnering Business Business Business EXAMPLES • Next-Generation Sequencing (NGS) • Mas
Slide 56: Tecan Partnering, a Well-Balanced Business
Tecan Partnering, a Well-Balanced Business INSTRUMENTS • Over 20 active instrument accounts • Several top IVD companies as well as emerging players SALES BY PRODUCT GROUP COMPONENTS • Market leader in liquid handling components Instruments • Portfolio optimized for a wide range of applications inclu
Slide 57: SIAS acquisition expands solution range
SIAS acquisition expands solution range with components, modules and systems for strategic PB market segments COMPLEMENTARY SIAS PRODUCTS AND EXPERTISE HISTOLOGY / CYTOLOGY MOLECULAR DIAGNOSTICS MS (SAMPLE PREP) BLOOD GROUPING / TYPING IMMUNOASSAYS 57
Slide 58: Portfolio differentiated to support OEM business models
Tecan’s portfolio is differentiated to support various business models for OEM customers worldwide COMPONENTS • Tecan supplies components and robotic modules for key applications • Option to customize components for specific customer needs • Customer develops system in-house with Tecan support PLATF
Slide 59: Growing Tecan's Partnering Business
Growing Tecan’s Partnering Business • Family of four instruments for IN RAMP Ortho Clinical Diagnostics UP PHASE • Dako Omnis for Agilent • Several Platform and Components accounts • Singulex Clarity NGI instrument ABOUT TO LAUNCH • High-throughput CLIA immunoassay system • New platform development
Slide 60: Supporting Significant Delivery Ramp-Up (1)
Supporting Significant Delivery Ramp-Up (1) IN RAMP UP DAKO OMNIS ADVANCED STAINING FOR AGILENT TECHNOLOGIES PLATFORM FOR TISSUE-BASED CANCER Setting new standards with regard DIAGNOSTICS ABOUT TO LAUNCH to flexibility, capacity, efficiency and traceability UPDATE • Continued global commercial uptak
Slide 61: Supporting Significant Delivery Ramp-Up (2)
Supporting Significant Delivery Ramp-Up (2) IN RAMP UP ORTHO VISION™ ANALYZER FOR NEXT-GENERATION DIAGNOSTICS ORTHO CLINICAL DIAGNOSTICS INSTRUMENT FOR BLOOD TYPING Transforming transfusion medicine UPDATE ABOUT TO LAUNCH with Responsive Automation • Significant increase in serial production to supp
Slide 62: Further Example (1): Liferiver Bio-Tech
Further Example (1): Liferiver Bio-Tech IN RAMP UP AUTRAX WORKSTATION ABOUT TO LAUNCH • Autrax is an automated workstation for nucleic acid extraction and reagent preparation targeting the MDx market • Key assays include Zika, Ebola and SARS UNDER DEVELOPMENT virus detection as well as several other
Slide 63: Further Example (2): DaAn Gene
Further Example (2): DaAn Gene IN RAMP UP DA3000 • DaAn Gene, a major supplier to the ABOUT TO LAUNCH Chinese IVD market for over 20 years • Automated DNA extraction system for infectious diseases testing in blood banks UNDER DEVELOPMENT • 4 Tecan Cavro ADP modules are integrated in the instrument P
Slide 64: Examples of recent Partnerships in China
Examples of recent Partnerships in China IN RAMP UP MOLECULAR DIAGNOSTICS ABOUT TO LAUNCH …and more UNDER DEVELOPMENT IMMUNOASSAYS PIPELINE …and more 64
Slide 65: Components for Next Gen Sequencing
Components for Next Gen Sequencing (NGS) IN RAMP UP TECAN CAVRO PUMPS ABOUT TO LAUNCH • Market-leading syringe pumps optimized for NGS applications are used in numerous sequencers from different providers • Allows further participation in the dynamic UNDER DEVELOPMENT growth of the NGS market in add
Slide 66: OEM Project Update: Singulex Clarity
OEM Project Update: IN RAMP UP • Several ClarityTM 0-series instruments installed at Singulex and trial sites • Continuous Expansion of assay menu by Singulex • Field service agreement with Tecan in place ABOUT TO LAUNCH • Singulex expects launch in Europe in 2016 and US FDA approval in 2H 2017 UNDE
Slide 67: High-Throughput Immunoassay Analyzer
High-Throughput Immunoassay Analyzer IN RAMP UP • Innovative approach allows ultra- high throughput processing and analysis of plate-based ABOUT TO LAUNCH immunoassays in an IVD setting • CLIA reader and system software with optimized features part of the development • Chemiluminescence (CLIA) as we
Slide 68: New Development Project with Top Company
New Development Project with Top 10 Company IN RAMP UP • Development signed with a Top 10 IVD company • Targeting a fast growing application ABOUT TO LAUNCH which is going to be deployed across research, IVD and applied market segments • Start of commercialization expected UNDER DEVELOPMENT 2018 • D
Slide 69: Inova Diagnostics
Inova Diagnostics IN RAMP UP • Inova Diagnostics ABOUT TO LAUNCH Leaders in the development and commercialization of new autoimmune systems and reagents • Part of Werfen UNDER DEVELOPMENT • QUANTA Lyser® family of analyzers based on Sias platform technology • Development and range extension of a fam
Slide 70: Current Funnel and Pipeline Projects
Current Funnel and Pipeline Projects IN RAMP UP COMPONENTS • Well-stocked pipeline of opportunities for Components as well as Platform and System ABOUT TO LAUNCH OTHERS Developments MOLECULAR • Over 20 active instrument projects DIAGNOSTICS PLATFORMS from feasibility to development, IMMUNO several i
Slide 71: Growing Tecan's Partnering Business
Growing Tecan’s Partnering Business IN RAMP UP PHASE …and more ABOUT TO LAUNCH …and more UNDER DEVELOPMENT …and more >20 instrument projects, PIPELINE including top 10 IVD companies 71
Slide 72: eFluidics – Technology Development Update
eFluidics – Technology Development Update Development Commercialization strategy • Development of MDx • Potential to commercialize and ELISA applications eFluidics under the Tecan brand as well as through the • Prototype instrument, Partnering Business channel development ongoing • Stand-alone syste
Slide 73: Launch of a new Partnering Business Field Service Offering
Launch of a new Partnering Business Field Service Product Offering COMPETITIVE DIFFERENTIATION AS A TOTAL SERVICE PROVIDER TO OUR OEM CUSTOMERS • Various Field Service options for Tecan Manufactured Instruments are available • Delivering professional service & support to the users of Tecan Partnerin
Slide 74: Summary
Summary PARTNERING BUSINESS OUTLOOK SALES BY PRODUCT GROUP • Ramp up of key launches ongoing • Clear focus on selected market segments with global presence Instruments • Multiple new developments in process and a healthy pipeline for components, platforms and system developments 41% Components 36% G
Slide 75: The Next Generation Immunodiagnostics (NGI) Company
The Next Generation Immunodiagnostics (NGI) Company Tecan Capital Markets Day Guido Baechler, President and Chief Executive Officer June 16, 2016
Slide 76: Singulex's Proprietary SMC Technology Delivers NGI
Singulex’s Proprietary SMCTM Technology Delivers NGI 100 times more sensitive than currently available platforms 76 | Singulex – The Next Generation Immunodiagnostics Company
Slide 77: Why Sensitivity Matters
Why Sensitivity Matters SMC™ enables earlier, precise definitive diagnosis – Competitors cannot meet demand SMC-POWERED DISEASE STATUS MONITORING Singulex SMC Assay Limit Healthy At Risk? Disease Typical cTnI Assay Limit European AMI Rule-out Guideline Cardiac Troponin 0.01 0.1 1.0 5.0 10 100 1000 R
Slide 78: SMC Provides NGI Cardiac Health Assessment
SMC Provides NGI Cardiac Health Assessment The power to distinguish disease before clinical symptoms 250'000 Singulex Clinical Laboratory RWD >444,000 patients Number of patient samples 200'000 >806,000 patient samples 150'000 RULE OUT DISEASE 100'000 DIAGNOSE DISEASE EARLIER 50'000 0 >15 10.5 11.5
Slide 79: SMC Provides NGI Cardiac Health Assessment (video)
SMC Provides NGI Cardiac Health Assessment The power to prevent (CLICK THE VIDEO TAB ON THE WEBCAST TO WATCH VIDEO) 79 | Singulex – The Next Generation Immunodiagnostics Company
Slide 80: SMC Used by World Class Key Opinion Leaders
SMC™ Used by World Class Key Opinions Leaders Network of internationally recognized physician and laboratory leaders Dirk J. van Veldhuisen Adriaan Voors Peter Vandermeer Thomas Brinkman Nick Mills Piotr Ponikowski John McMurray Wolfgang Koenig Allan Jaffe Paul Collinson Christian Mueller Richard Po
Slide 81: NGI has Broad Applications
NGI has Broad Applications SMC technology will drive NGI clinical value Rule Out Unnecessary Rule Out Disease Expensive Procedures • Cardiovascular disease • Heart Attack / AMI • Cardiovascular Stress Tests • Concussion / Alzheimer’s • Laparoscopic procedures • Angiography SMC Technology Early Detec
Slide 82: Singulex SMC Technology Primed for Strong Growth
Singulex SMC Technology Primed for Strong Growth Validated in multiple ways SMC-generated data from more than 130,000 patients presented in over 110 independent peer-reviewed publications. SMC protected by broad global intellectual property portfolio (30 granted and 39 filed and pending patents). EM
Slide 83: Proven Success in NGI - $45M Revenue in 2015
Proven Success in NGI - $45M Revenue in 2015 Rapid value creation in multiple business areas – poised to expand 2007 2010 2013 2015 2016 2017 Life Science Business Making SMC™ the global NGI gold standard AND creating diagnostic Erenna opportunities Research Use Only (RUO) In-Vitro Diagnostics (IV
Slide 84: Proven Success in NGI - $45M Revenue in 2015
Proven Success in NGI - $45M Revenue in 2015 Rapid value creation in multiple business areas – poised to expand 2007 2010 2013 2015 2016 2017 Life Science Business Life Science Business Licensed to Merck Millipore Erenna in July 2015 Clinical Laboratory Business Clinical Lab Business: 2015 revenue:
Slide 85: SMC-Powered Sgx Clarity System is fully developed
SMC-Powered Sgx ClarityTM System is fully developed Delivering NGI to hospital and any clinical lab, CE Mark expected Q4 2016 Fully developed automated system Value driver for hospital & reference labs: • Cost savings • Increase revenue • Improved patient care Timeline from initial development t
Slide 86: Sgx Clarity System Developed in ~3 Years
Sgx Clarity™ System Developed in ~ 3 Years Development of assays, software and hardware in unprecedented speed Begin European Zero Series Market Evaluations instruments Begin US Clinical Demo and pre-M4 delivered Trials (July) Project Initiation instruments Instrument CE Mark (Q4) De
Slide 87: Clarity Market Evaluation Started in Barcelona
Clarity Market Evaluation Started in Barcelona The first Clarity has been installed in a Hospital* Systems works very reliably and the clinical data created is beyond the expectation of the customer… 87 | Singulex – The Next Generation Immunodiagnostics Company * For Investigational Use Only
Slide 88: Sgx Clarity European Commercialization Strategy
Sgx Clarity European Commercialization Strategy Use early adopters to expand local customer base Barcelona installed in May 2016, expect first commercial sale end of 2016. KOL: Jordi Llanos Allesandro Sionis Hospital de Sant Pau; Barcelona; Spain 88 | Singulex – The Next Generation Immunodiagnos
Slide 89: The Demand for NGI is Real
The Demand for NGI is Real SMC Offers Proven Clinical Impact In 2009, cardiologists did not know cardiac troponin could be measured in healthy people. Today, Singulex’s revelation of the clinical value of low level cTnI measures has made it the most relevant cardiac biomarker. SMC Demonstrated Resul
Slide 90: Thank You
Thank You Information herein pertaining to and other Singulex proprietary lab developed tests are based on testing services provided by the licensed Singulex Clinical Labor atory. Information herein pertaining to Sgx Clarity TM and associated assays are in development, and not available for commerci
Slide 91: Growing Consumables Business
Capital Markets Day GROWING CONSUMABLES BUSINESS KLAUS LUN, EXECUTIVE VP CORPORATE DEVELOPMENT
Slide 92: Consumables business represents 11% of overall sales
Consumables business represents today 11% of our overall sales Consumables sales 2010-2015 Share of recurring revenue sales in 2015 Products • Consumables revenues with historical annual growth rate of 10%+ 5% 11% • Share of consumables increased from 8% to 11% between 2010 and 2015 22% 62% • Contin
Slide 93: Several trends to drive consumption of consumables
Several trends to drive consumption of consumables CONSUMPTION DRIVER TRENDS Tecan selling more disposable instruments over fixed tips instruments (also driven by new Fluent platform) CD CDx is moving to disposable tips to avoid cross contamination and x driven by (new) applications (e.g. NGS, NGI,
Slide 94: Current consumable product portfolio
Tecan current consumable product portfolio – primarily linked to Liquid Handling (LiHA) instrumentation… Consumable portfolio Filtered LiHa (Best in class with 98% MPPS, Permeability 1.9%, HEPA class NOT Filtered H11 and H10) Standard tray SBS format Nested 350ul Variants LiHa tips LiHa tips LiHa ti
Slide 95: Broader lab plasticware market
…but we operate within a much broader Lab plastic ware market LAB PLASTICWARE MARKET DEFINITION Automation tips Manual tips Tips Microtiter Specialist and Microtiter Plates plates functional plate lids microtiter plates Plastic Micro tubes, Microfluidics bottles, sample tubes, and other Cuvettes con
Slide 96: Consumables Strategy Growth Pillars
Consumables Strategy Growth Pillars AUTOMATION CONSUMABLES MARKET (TIPS, PLATES, LABWARE) Current market: USD 1.2BN+ market STRATEGIC GROWTH PILLARS POTENTIAL MARKET 1 Address installed Fixed tips based Tecan (non-disposable tips) New adjacent consumables 2 products 2 Drive uptake of instruments usi
Slide 97: Best positioned to drive integrated sales of consumables
Tecan is best positioned to drive the integrated sales of its consumables + Instrument Hardware design to best suit our consumables ✓ Own design of consumables ✓ Instrument software and liquid detection High end manufacturing and in-line optimized & validated for our consumables ✓ quality control ✓
Slide 98: You're Assured
YOU’RE ASSURED . At Tecan, we work continually to provide assurance to our customers that their tests and experiments are carried out to the highest standards of performance – down to every single tip
Slide 99: M&A as Competitive Advantage
Capital Markets Day M&A AS COMPETITIVE ADVANTAGE KLAUS LUN, EXECUTIVE VP CORPORATE DEVELOPMENT
Slide 100: Appropriate, Thoughtful M&A as Key Growth Driver
Appropriate, Thoughtful M&A as Key Growth Driver Life Science and M&A strategy at Tecan Healthcare M&A (USD bn)* 200 150 Corp M&A Target Target Target Target Strategy Strategy Identicat. Cultivation Acquisition Integration 100 • Key element of the corporate strategy 50 • Executed in a very structure
Slide 101: Key Reasons for Driving M&A at Tecan
Key Reasons for Driving M&A at Tecan Deploy existing capital to increase investors Use balance sheet to drive return and use healthy financials to also 1 more growth drive larger deals Support transition of company Use reagent content to leverage installed 2 into a solution provider base to develop
Slide 102: Tecan M&A vectors aligned with corporate growth strategy
Tecan M&A vectors aligned with corporate growth strategy LIFE SCIENCE RESEARCH IN-VITRO DIAGNOSTICS STRATEGIC PILLARS CAGR +3-5% +3-5% 1 Scale & capability > 40 BN USD > 40 BN USD Reagents & Consumables 3 Reagents & Consumables 2 Build additional pillars and 2 Instruments complete portfolio Instrume
Slide 103: IBL and Sias acquisitions tick the boxes
IBL and Sias acquisitions tick the boxes – Deal characteristics unchanged • Leverage broad application know-how and experience to develop assay specific solution optimized for a platform • Own the assay know-how and have dedicated instrumentation (develop proprietary solutions) • High consum
Slide 104: Well positioned to deploy several hundreds of million of capital
Well positioned to deploy several hundreds of million of capital over the next years Pipeline includes larger, transformative deals Continue to execute on smaller bolt-on acquisitions Company funnel well filled, with various projects at different stages 104
Slide 105: D&O – Driving Operational Excellence
Capital Markets Day D&O – DRIVING OPERATIONAL EXCELLENCE ULRICH KANTER, EXECUTIVE VP, HEAD DEVELOPMENT & OPERATIONS
Slide 106: Development and Operations (D&O)
Development and Operations (D&O) D&O PRIORITIES • Increasing R&D efficiency – drive innovation • Excellence in Supply Chain Management • Excellence in Manufacturing Mainz, DE Grödig/Salzburg, AT San Jose, US Männedorf/Zürich, CH Hamburg, DE 106
Slide 107: Strategic directions towards D&O priorities
Strategic directions towards DO priorities Focus • Organizational Productivity alignment • Enhanced • Lean principles Synergies @ Integration Accountability • Visual Mgmt. • Core • Standardization competencies • Agile Global for modules, • KPIs • Design thinking technologies • Flow production and in
Slide 108: Achievements since last CMD: R&D
Achievements since last CMD: R&D New R&D Management and organization R&D TEST AREA IN THE PAST implemented • Impact on methods, processes and culture • Common targets with Operations Definition of core competencies for R&D in Foto Männedorf completed RnD Testfläche / neues Layout • Areas for outsour
Slide 109: Achievements since last CMD: Operations
Achievements since last CMD: Operations New Product line management and organization implemented • Factory-in-Factory principle with enhanced accountability Shift from Cell to Flow production to reduce WIP (work in progress) and standardize labor time New shop floor management focus on Lean • Signif
Slide 110: Progressing on the Learning Curve
CASE STUDY FOR A MAJOR PLATFORM Progressing on the Learning Curve LEAN AT TECAN Change to Line-Flow-Principle • Significant improvements in hours of labor time to produce each instrument Change to One-Piece-Flow in 2016 • Kan Ban module assembly – ship to line 100 % 100 Ave. time per unit in % 80 70
Slide 111: COGS Improvements
CASE STUDIES COGS Improvements COMPLEX DIE CASTED PART RELOCATED TO ASIAN SUPPLIER Prior to relocation After relocation 448 CHF 106 CHF With the same design, the realized savings were 76% SAND CASTED STRUCTURE SUPPLIER RELOCATION In the process of relocation of sand casted chassis With the same desi
Slide 112: Sias Integration
Sias Integration COMPLETE SIAS INTEGRATION • Legal integration completed • Site consolidation planned to be completed by Q3 2016 • Drive synergies for R&D and Operations • New shop floor management and one Xantus 440H-150 piece flow production at Tecan enables integration of former SIAS production l
Slide 113: Next steps
Next steps R&D Further strengthen global R&D governance • Enforce defined standards and architectures Global definition and rollout of R&D processes and milestone deliverables Increased focus on technology and innovation OPERATIONS Continue supply chain restructuring with focus on • Supplier relocat
Slide 114: Empowering Life Sciences and Diagnostics
Tecan Group Capital Markets Day EMPOWERING LIFE SCIENCES AND DIAGNOSTICS DR. DAVID MARTYR, CEO
Slide 115: Advancing Tecan
Advancing Tecan • Accelerating topline growth • 2015: +13.1%, highest rate since 2006 SALES • Outgrowing the market • Organic: +9.6%, clearly above market • Expand operating margins • 2015: EBITDA margin up by 200 bps PROFITABILITY • Focus on operational efficiency • Net profit even stronger • M&A t
Slide 116: Advancing Tecan: Sales
Advancing Tecan: Sales SALES • Significant topline momentum in both business SALES DEVELOPMENT divisions • Positioned to outgrow the market 450.0 440.3 PROFITABILITY • Strong performance from recurring revenue 430.0 CHF (mio) sources 410.0 399.5 391.1 388.3 • 2016 expected to be another double-digit
Slide 117: Advancing Tecan: Profitability
Advancing Tecan: Profitability SALES • Continue to expand underlying profit margins 2016 OPERATING PROFIT (EBITDA) and beyond 90.0 83.4 • Key factors impacting future margin development: PROFITABILITY 80.0 CHF (mio) + 70.0 63.0 65.1 67.5 • Increased operating efficiency with focus on material 60.4 c
Slide 118: Advancing Tecan: Capital Deployment
Advancing Tecan: Capital Deployment SALES • M&A as the primary focus of capital deployment OPERATING CASH FLOW • Increased dividend to CHF 1.75, roughly 99.1 100.0 maintaining yield and payout ratio PROFITABILITY 80.0 • Prepared for larger, transformative deals in CHF (mio) addition to continued bol
Slide 119: Advancing Tecan: Culture & Brand
Advancing Tecan: Culture & Brand SALES • Tecan is a leading brand in life sciences and diagnostics and the leading brand in lab automation • Refreshed branding and increased focus on PROFITABILITY brand equity • New company values and other elements impacting culture rolled out globally • Continue t
Slide 120: Summary
OUTGROWING MARKET ORGANICALLY • Life Sciences Business with new and leading product portfolio and improved organization • Partnering Business with major platform in ramp up phase and broad pipeline INCREASING PROFITABILITY • Committed to drive profitability higher together with sales growth • Cash f
Slide 121: Agenda
Agenda Advancing Tecan David Martyr Life Sciences Business 08:45 – 10:00 Strategy and Growth Drivers Stefan Traeger Customer Needs Driving Solutions James O’Brien Expanding Our Reagents Business Geert Nygaard 10:00 – 10:15 Coffee Break Partnering Business Strategy and Growth Drivers Achim von Leopre
Slide 122: Q&A, IR iPad App, Contact
Q&A IR IPAD APP CONTACT News, financial reports, Martin Braendle presentations, Vice President, Communications & IR videos and more Phone: +41 (0) 44 922 84 30 investor@tecan.com NEXT EVENT 2016 www.tecan.com August 16: Half Year Results 2016 122
Slide 123: Thank you for your attention.
Thank you for your attention. The webcast and presentations end Day continues with • site tour at Tecan Headquarters in Maennedorf • live demos of some instruments 123
Slide 124: «a a em
5 «a a em J td ~ | 7 2 ¢ Empowered |, |
Slide 125: Tecan – Who we are
Tecan – Who we are Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the lif